Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

Allogene has staked its claim in iPS cell-based allogeneic therapies by partnering with Notch to develop T cell and NK cell therapies to treat non-Hodgkin lymphoma, leukemia and multiple myeloma.

Moving beyond healthy donor cells to use iPS cells for

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers